TrialJournal of the European Academy of Dermatology and Venereology : JEADV2026

Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis.

Nassr Nassr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.